Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 53 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 7678552

    Method for selecting therapeutic agents for cancer treatment

    Precision Therapeutics, Inc. · Granted Mar 16, 2010 · Expires Mar 11, 2030

    granted

  2. US 7678890

    Compositions and methods of treating disease with FGFR fusion proteins

    Five Prime Therapeutics, Inc. · Granted Mar 16, 2010 · Expires Mar 11, 2030

    granted

  3. US 7662619

    Sol-fusin: use of GP64-6His to catalyze membrane fusion

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Feb 16, 2010 · Expires Feb 11, 2030

    granted

  4. US 7655252

    Antimicrobial nanoemulsion compositions and methods

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Feb 2, 2010 · Expires Jan 28, 2030

    granted

  5. US 7648826

    Detecting CYP24 expression level as a marker for predisposition to cancer

    The Regents of the University of California · Granted Jan 19, 2010 · Expires Jan 14, 2030

    granted

  6. US 7645441

    Compositions and methods in cancer associated with altered expression of PRLR

    Sagres Discovery, Inc. · Granted Jan 12, 2010 · Expires Jan 7, 2030

    granted

  7. US 7635474

    VEGF-binding fusion proteins

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 22, 2009 · Expires Dec 17, 2029

    granted

  8. US 7608268

    Ferritin fusion proteins for use in vaccines and other applications

    New Century Pharmaceuticals, Inc. · Granted Oct 27, 2009 · Expires Oct 22, 2029

    granted

  9. US 7605251

    Compositions and methods for inhibiting expression of the PCSK9 gene

    Alnylam Pharmaceuticals, Inc. · Granted Oct 20, 2009 · Expires Oct 15, 2029

    granted

  10. US 7605131

    EML4-ALK fusion gene

    CUREGENE K.K. · Granted Oct 20, 2009 · Expires Oct 15, 2029

    granted

  11. US 7604944

    Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same

    Theravance, Inc. · Granted Oct 20, 2009 · Expires Oct 15, 2029

    granted

  12. US 7601516

    Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for the treatment of infertility

    Syntonix Pharmaceuticals, Inc. · Granted Oct 13, 2009 · Expires Oct 8, 2029

    granted

  13. US 7598341

    Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs

    The Regents of the University of California · Granted Oct 6, 2009 · Expires Oct 1, 2029

    granted

  14. US 7598077

    Compositions and methods for enhancing differential expression

    The United States of America, as represented by the Department of Health and Human Services · Granted Oct 6, 2009 · Expires Oct 1, 2029

    granted

  15. US 7585653

    Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same

    Theravance, Inc. · Granted Sep 8, 2009 · Expires Sep 3, 2029

    granted

  16. US 7582745

    Compositions and methods for inhibiting expression of Nav1.8 gene

    Alnylam Pharmaceuticals, Inc. · Granted Sep 1, 2009 · Expires Aug 27, 2029

    granted

  17. US 7576065

    Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 18, 2009 · Expires Aug 13, 2029

    granted

  18. US 7563593

    Method for preparing cell cultures from biological specimens for assaying secreted factors

    Precision Therapeutics, Inc. · Granted Jul 21, 2009 · Expires Jul 16, 2029

    granted

  19. US 7550275

    Expression, purification and uses of a Plasmodium falciparum liver stage antigen 1 polypeptide

    United States of America as represented by the Secretary of the Air Force · Granted Jun 23, 2009 · Expires Jun 18, 2029

    granted

  20. US 7544486

    Nell peptide expression systems and bone formation activity of nell peptide

    The Regents of the University of California · Granted Jun 9, 2009 · Expires Jun 4, 2029

    granted

  21. US 7534604

    Fusion polypeptides capable of activating receptors

    REGENERON PHARMACEUTICALS, INC. · Granted May 19, 2009 · Expires May 14, 2029

    granted

  22. US 7534440

    Fusion molecules and methods for treatment of immune diseases

    The Regents of the University of California · Granted May 19, 2009 · Expires May 14, 2029

    granted

  23. US 7524516

    Corrosion inhibiting mildew remover kit

    United States of America as represented by the Secretary of the Air Force · Granted Apr 28, 2009 · Expires Apr 23, 2029

    granted

  24. US 7501260

    Methods for determining efficacy of chemotherapeutic agents for a patient prior to treatment

    Precision Therapeutics, Inc. · Granted Mar 10, 2009 · Expires Mar 5, 2029

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.